Kits Eyecare Expects Q3 Sales To Exceed $41 Million
Kits Eyecare (TSX: KITS) has raised its guidance for the third quarter following a strong week of sales to close out the month of August.
The eyecare company reportedly saw $3.5 million in sales for the week ended August 31, 2024, a record-breaking week for the company. As a result, the company has now declared that Q3 revenue will exceed the previously provided range of $39 to $41 million.
The revised outlook is said to call for over 32% growth in year over year topline revenue.
Adjusted EBITDA meanwhile is expected to remain in a range between 3% and 5% of revenue.
Kits Eyecare last traded at $10.90 on the TSX.
Information for this story was found via the sources mentioned within the article. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.